Austin Reilly, MD
Pain Medicine · Elkhorn, NENPI 1508358987
Payments from drug & device makers
Across 425 payments — averaging $79.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$12K
- Boston Scientific$7K
- Medtronic$5K
- Saluda Medical Americas, Inc.$4K
- Si-bone, Inc.$1K
- AbbVie$1K
- plus $3K from 28 others
What the payments were for
- Grants$3,0309%
- Travel & lodging$13,90041%
- Food & beverage$16,90050%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 72 | $11,738 |
| Boston Scientific | 82 | $7,253 |
| Medtronic | 58 | $4,812 |
| Saluda Medical Americas, Inc. | 43 | $4,155 |
| Si-bone, Inc. | 16 | $1,378 |
| AbbVie | 55 | $1,061 |
| Nalu Medical, Inc. | 11 | $894 |
| Nevro Corp. | 10 | $820 |
| Pfizer | 20 | $337 |
| Painteq LLC | 2 | $258 |
| SPR Therapeutics, Inc | 4 | $157 |
| Vertex | 6 | $140 |
| Averitas Pharma Inc. | 6 | $129 |
| Collegium Pharmaceutical, Inc. | 7 | $125 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $71 |
| Lundbeck LLC | 3 | $66 |
| Stryker | 2 | $51 |
| Lilly USA, LLC | 3 | $49 |
| Scilex Pharmaceuticals Inc. | 3 | $49 |
| Impel Pharmaceuticals Inc. | 2 | $31 |
| Amgen | 2 | $29 |
| Forte Bio-pharma LLC | 2 | $27 |
| Octapharma USA, Inc. | 1 | $27 |
| Biotronik NRO, Inc. | 1 | $20 |
| Bioventus LLC | 1 | $20 |
| Stratus Medical, LLC | 1 | $18 |
| Pacira Pharmaceuticals Incorporated | 1 | $18 |
| Relievant Medsystems, Inc. | 1 | $16 |
| Protega Pharmaceutials Inc | 1 | $16 |
| Fidia Pharma USA Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Convatec Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Stimwave Technologies Incorporated | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROCLAIM$6,921
- Evoke$3,349
- INTELLIS ADAPTIVESTIM$1,650
- KYPHON EXPRESS II KYPHOPAK TRAY$844
- IFUSE IMPLANT SYSTEM$796
- Superion Indirect Decompression System$693
- GENERAL - THERAPIES$656
- SYNCHROMEDII$654
- WaveWriter Alpha Prime 16$589
- Nalu Neurostimulation System$563
- Intracept$498
- Senza$497
- ETERNA$403
- PAINTEQ$227
- Evoke SCS$206
- GENERAL PAIN MANAGEMENT$138
- OSTEOCOOL RF ABLATION SYSTEM$109
How this compares
$33,831 in reported general payments places this provider in the 95th percentile of 31 pain medicine providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine | 61 | $16,103 |
| BelbucaBuprenorphine Hcl | 15 | $10,348 |
| Pregabalin | 140 | $3,475 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 107 | $2,722 |
| Gabapentin | 228 | $2,329 |
| Cyclobenzaprine Hcl | 234 | $2,323 |
| Celecoxib | 38 | $1,200 |
| Duloxetine Hcl | 70 | $1,070 |
| Tramadol Hcl | 94 | $979 |
| Tizanidine Hcl | 70 | $961 |
| Methocarbamol | 36 | $668 |
| Meloxicam | 182 | $599 |
| Buprenorphine Hcl | 29 | $538 |
| Amitriptyline Hcl | 23 | $330 |
| Cephalexin | 25 | $192 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca | $125 | $10,34815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 31 pain medicine providers in Nebraska.
Other pain medicine in Elkhorn
- Phillip EssayLincoln$63K
- Charles WhittenLincoln$27K
- Matthew StottleOmaha$14K
- John MasseyLincoln$13K
- Liane DonovanLincoln$13K
- Katie BerkyOmaha$12K
- Dongyup LeeGrand Island$11K
- Ihsan BalkayaNorfolk$10K
- Tyrus SoaresOmaha$8K
- Apollo StackOmaha$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.